ciclopirox has been researched along with Colorectal Neoplasms in 4 studies
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "However, the effects of CPX on colorectal cancer (CRC) and the underlying mechanisms for its antitumor activity remain unclear." | 5.56 | Ciclopirox activates PERK-dependent endoplasmic reticulum stress to drive cell death in colorectal cancer. ( Chen, Q; Chen, T; Deng, Y; Li, L; Lu, B; Mo, S; Qi, J; Shan, C; Zhou, N; Zhou, Y, 2020) |
| "However, the effects of CPX on colorectal cancer (CRC) and the underlying mechanisms for its antitumor activity remain unclear." | 1.56 | Ciclopirox activates PERK-dependent endoplasmic reticulum stress to drive cell death in colorectal cancer. ( Chen, Q; Chen, T; Deng, Y; Li, L; Lu, B; Mo, S; Qi, J; Shan, C; Zhou, N; Zhou, Y, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, J | 1 |
| Zhang, L | 1 |
| Wang, M | 1 |
| Zhou, L | 1 |
| Feng, X | 1 |
| Yu, L | 1 |
| Lan, J | 1 |
| Gao, W | 1 |
| Zhang, C | 1 |
| Bu, Y | 1 |
| Huang, C | 1 |
| Zhang, H | 1 |
| Lei, Y | 1 |
| Huang, YM | 1 |
| Cheng, CH | 1 |
| Pan, SL | 1 |
| Yang, PM | 1 |
| Lin, DY | 1 |
| Lee, KH | 1 |
| Qi, J | 1 |
| Zhou, N | 1 |
| Li, L | 1 |
| Mo, S | 1 |
| Zhou, Y | 1 |
| Deng, Y | 1 |
| Chen, T | 1 |
| Shan, C | 1 |
| Chen, Q | 1 |
| Lu, B | 1 |
| Song, S | 1 |
| Christova, T | 1 |
| Perusini, S | 1 |
| Alizadeh, S | 1 |
| Bao, RY | 1 |
| Miller, BW | 1 |
| Hurren, R | 1 |
| Jitkova, Y | 1 |
| Gronda, M | 1 |
| Isaac, M | 1 |
| Joseph, B | 1 |
| Subramaniam, R | 1 |
| Aman, A | 1 |
| Chau, A | 1 |
| Hogge, DE | 1 |
| Weir, SJ | 1 |
| Kasper, J | 1 |
| Schimmer, AD | 1 |
| Al-awar, R | 1 |
| Wrana, JL | 1 |
| Attisano, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1 Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy[NCT00990587] | Phase 1 | 20 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ciclopirox and Colorectal Neoplasms
| Article | Year |
|---|---|
Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers.
Topics: Acute Disease; Administration, Oral; Benzoates; beta Catenin; Cell Line, Tumor; Cell Proliferation; | 2011 |
3 other studies available for ciclopirox and Colorectal Neoplasms
| Article | Year |
|---|---|
CPX Targeting DJ-1 Triggers ROS-induced Cell Death and Protective Autophagy in Colorectal Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Death; Cell Line, Tumor; Ciclopirox; Colo | 2019 |
Gene Expression Signature-Based Approach Identifies Antifungal Drug Ciclopirox As a Novel Inhibitor of HMGA2 in Colorectal Cancer.
Topics: Antifungal Agents; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Ciclo | 2019 |
Ciclopirox activates PERK-dependent endoplasmic reticulum stress to drive cell death in colorectal cancer.
Topics: Aerobiosis; Animals; Apoptosis; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cel | 2020 |